Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18725648 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
Conditions: Breast Cancer;   Low Bone Mineral Density;   Osteopenia
Interventions: Drug: Placebo;   Drug: AMG 162 / Denosumab

Indicates status has not been verified in more than two years